DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a major dental equipment manufacturer, is facing a securities fraud class action lawsuit over alleged misconduct related to its Byte direct-to-consumer aligner product. The lawsuit, filed on behalf of investors who purchased DENTSPLY stock between May 6, 2021, and November 6, 2024, alleges that the company made false and misleading statements about Byte's safety and financial impact.
According to the complaint, DENTSPLY targeted low-income individuals who lacked access to proper dental care for its Byte aligner treatment. This allegedly resulted in patients with underlying dental issues that should have made them ineligible for treatment being approved for Byte aligners. The lawsuit claims that DENTSPLY's push for growth and sales commissions led employees to sell to contraindicated patients, and that the company's onboarding process failed to adequately screen out unsuitable candidates.
The allegations further state that DENTSPLY was aware of numerous reports of patient injuries caused by Byte aligners but did little to investigate these incidents or notify the U.S. Food and Drug Administration (FDA). The company is accused of lacking proper systems to report such injuries to the FDA within the required 30-day timeframe. Meanwhile, the FDA reportedly experienced a sharp increase in reports of serious injuries among Byte patients.
As a result of these issues, the lawsuit claims that DENTSPLY materially overstated the goodwill value of Byte on its financial statements. The company's positive statements about its business, operations, and prospects are alleged to have been materially false, misleading, or lacking a reasonable basis throughout the class period.
This legal action highlights potential risks for investors in the rapidly growing direct-to-consumer dental aligner market. It also raises questions about regulatory oversight and patient safety in the teledentistry sector. The case could have significant implications for DENTSPLY's financial position and reputation in the dental industry.
Investors who purchased DENTSPLY stock during the specified period and suffered losses may be eligible to participate in the class action lawsuit. The lead plaintiff deadline is set for January 27, 2025. Kessler Topaz Meltzer & Check, LLP, the law firm handling the case, is encouraging affected investors to contact them for more information about their legal rights and options.
The outcome of this lawsuit could have broader implications for the dental industry, potentially leading to increased scrutiny of direct-to-consumer orthodontic products and stricter regulations for patient screening and safety monitoring in teledentistry. It may also prompt investors to more closely examine the business practices and risk disclosures of companies operating in this sector.
